Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LB 001

Drug Profile

LB 001

Alternative Names: LB-001

Latest Information Update: 18 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LogicBio Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Methylmalonyl-CoA mutase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methylmalonic acidaemia
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Methylmalonic acidaemia

Most Recent Events

  • 10 Feb 2020 The US FDA places a clinical hold on LogicBio Therapeutic's IND application in USA for Methylmalonic academia
  • 10 Jan 2020 LogicBio Therapeutics files an IND application with the FDA in USA for Methylmalonic academia
  • 13 Aug 2019 LogicBio Therapeutics plans a phase I/II trial for Methylmalonic acidaemia (In Children) in the first half of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top